Cornerstone Wealth Management’s AstraZeneca AZN Stock Holding History

Cornerstone Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$518K	Buy	2,730 +714	+35%	+$134K	0.02%	484
2026 Q1	$398K	Buy	2,016 +851	+73%	+$164K	0.02%	507
2025 Q4	$214K	Buy	+1,165	New	+$204K	0.01%	643

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cornerstone Wealth Management's AZN Position: Q2 2026 in Review

Cornerstone Wealth Management increased its AstraZeneca (AZN) stake by 35% in Q2 2026, buying an estimated $134K and bringing the position to 2,730 shares worth $518K. The position accounts for 0.02% of the portfolio, ranked #484.

Cornerstone Wealth Management first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cornerstone Wealth Management held 2,730 shares of AstraZeneca worth $518K as of Q2 2026.
Cornerstone Wealth Management bought 714 AstraZeneca shares in Q2 2026, an estimated $134K.
AstraZeneca made up 0.02% of Cornerstone Wealth Management's portfolio in Q2 2026, its #484 holding.
Cornerstone Wealth Management first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cornerstone Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.